Skip to main content

”la Caixa” leads an investment round in IRB Barcelona's spin off Inbiomotion

Images

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

The company concludes a 2.2 million € round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital and Fundación Vila Casas.

Inbiomotion, a spin off founded by IRB Barcelona's group leader, Roger Gomis,  develops diagnostic products for predicting risks that cancer patients may suffer bone metastasis.

”la Caixa” has led a 2.2 million Euro investment round in the Inbiomotion company, a spin off founded by the ICREA Research Rrofessor Roger Gomis, group leader of the Growth control and cancer metastasis laboratory at the IRB Barcelona. Also participating in the Inbiomotion operation are Ysios Capital, the leading Spanish venture capital for the biotech sector, through its Ysios BioFund I fund, and Fundación Vila Casas, which were already shareholders of the company.
 
Inbiomotion develops diagnostic tests for predicting the risk that cancer patients may suffer bone metastasis. Bone metastasis occurs when a tumour growing in another part of the patient’s body spreads out through the bloodstream, overcomes all of the body’s defences, and colonises itself in the bone. These metastatic cancers are usually highly aggressive, painful, and ultimately result in the patient’s death.

The target market for Inbiomotion is patients with prostate or breast cancer, where bone is the most common site for metastasis. Some 75% of women with metastatic breast cancer and 90% of men with metastatic prostate cancer develop bone metastasis during the course of their disease. This will also happen with 15-30% of patients with other types of tumours, such as lung, colon, stomach, uterine, rectal, thyroid, or kidney.

More information: Caixa Capital Risk (press release)

MEET OUR SCIENTISTS VIDEOS: Roger Gomis: "LIGHT AND CREDIBILITY" (2.56 minutes)

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).